Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
Mr. Robison most recently was an Executive Vice President of Pfizer, Inc. until he retired in 2001. He joined Pfizer, Inc. in 1961 and served within Pfizer’s pharmaceutical sales organization to become Senior Vice President of Sales for Pfizer Labs. He was subsequently named General Manager for Pratt Pharmaceuticals and in 1992 was named President of Pfizer’s Consumer Healthcare Group and made a Pfizer Corporate Officer. In 1996 he joined Pfizer’s Corporate Management Committee and was promoted to the position of Executive Vice President and Head of Worldwide Corporate Employee Resources.
Mr. Robison currently serves as a director of several healthcare companies and is also on the Board of Trustees of the
Mr. Robison said, “It is a great pleasure to be a part of an exciting and growing company like Lakewood-Amedex. Its broad anti-bacterial and targeted anti-viral products hold great promise for the healthcare industry and could save numerous lives in the future. At the appropriate time we will aggressively seek pharmaceutical companies to work with us in the commercial development of our products.”
About Lakewood-Amedex, Inc.
Lakewood-Amedex is a privately held development-stage biopharmaceutical company with a broad patent portfolio of inventions, including, 24 granted and/or issued patents and 45 patent applications covering its proprietary NuBiotics family of anti-microbial products, proven to be effective against a wide range of bacteria, encompassing antibiotic resistant strains including methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas and others, and patents covering certain proprietary products targeting pandemic viral infections including, Epstein Barr Virus (EBV), human and avian influenza, Hepatitis B and C and other clinical indications. The Company anticipates initiating human clinical trials for topical use of its Nu-3 NuBiotics(R) compound in the near future for indications including; diabetic ulcers and other topical infections. Future studies will involve the use of Nu-2(R) to treat broad spectrum antibiotic-resistant bacterial pulmonary and systemic infections. The company is currently conducting a human IRB clinical study to improve treatment of nasopharyngeal carcinoma in
SOURCE Lakewood-Amedex, Inc.